ARVN News and Press, Arvinas Inc. From 12/15/20

Looking To Add Biotech Stocks To Your Watchlist? 3 Making Moves This Week It has clearly been the year of biotech stocks in the stock market. Investors and biotech companies alike will likely agree. Most of the top biotech stocks have seen massive rallies throughout this yea...

Arvinas (ARVN) initiates an underwritten pubic offering of $250M of its common stock. Price, size and terms are yet to be determined.Underwriters' overallotment option is to purchase up to an additional $37.5M of its common stock.Previously: Arvinas gains on protein degrader data (Dec. 1...

Gainers: BioCardia (BCDA) +102%.Arvinas (ARVN) +91%.Rubius Therapeutics (RUBY) +56%.Veru (VERU) +48%.AnPac Bio-Medical Science (ANPC) +45%.Homology Medicines (FIXX) +32%.ReneSola (SOL) +32%.Alexion Pharmaceuticals (ALXN) +31%.BioLineRx (BLRX) +30%.Big Rock Partners Acquisition (BRPA...

Gainers: Arvinas (ARVN) +97%, Rubius Therapeutics (RUBY) +95%, AnPac Bio-Medical Science (ANPC) +67%, Veru (VERU) +46%, BioCardia (BCDA) +31%.Losers: Aerpio Pharmaceuticals (ARPO) -47%, SELLAS Life Sciences (SLS) -27%, Greenwich Life...

Arvinas (ARVN) soars 97% in premarket after it says interim Phase 1 data for ARV-471 show evidence of anti-tumor activity and robust efficacy signals in heavily pretreated patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.Data showed one confirme...

AnPac Bio-Medical Science (ANPC) +99% as company makes significant progress in detecting pre-cancer diseases.Arvinas (ARVN) +74% after releasing interim clinical data of PROTAC® protein degraders.Veru (VERU) +57% on positive phase 2 clinical trial results for Enobosarm.Syn...

– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated patient population – – Initiation of a combination trial of ARV...

– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET – NEW HAVEN, Conn., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...

During a strong uptrend, certain stocks will be under distribution or show signs of weakness. These will lead on the downside, when the market turns. Four stocks in this category are WWE, COHR, EYEN, and ARVN. The market is quite strong and approaching new highs from a couple of weeks ago...

NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming virtual investor conferences: ...